Lupin Limited

Update in progress

LUPIN.NS (NSE)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Lupin Limited and its subsidiaries operate as a pharmaceutical company with a global presence, including India and the United States. It has two segments: Pharmaceuticals and Others. The company discovers, develops, manufactures, markets, and sells branded and generic formulations, biosimilars, APIs, and OTC and specialty medicines. It serves multiple therapeutic areas, provides diagnostics and digital health services, and runs a network of labs. Lupin collaborates with TB Alliance on Telacebec. Founded in 1968 and based in Mumbai, India.

Company score

Sentiment: 2.24; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.96; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 1.25; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.28; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.76; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 1.50; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive